Gentian Diagnostics ASA — Director's Dealing 2017

Jan 20, 2017

Mandatory notification of trade of primary insider

Mandatory notification of trade of primary insider

Reference is made to the stock exchange release from Gentian

Diagnostics AS ("Gentian" or the "Company") published

yesterday regarding the contemplated private placement of up

to NOK 100 million by issuance of up to 2,857,143 new shares

at NOK 35 per share (the "Private Placement").

The Company announced today that it has placed 2,714,286 new

shares (corresponding to NOK 95,000,010 in gross proceeds)

in Tranche 1 of the Private Placement.

In connection with the Private Placement Trance 1, the

following primary insiders have been allocated for shares in

Gentian Diagnostics AS:

Chief Financial Officer Julie Alling Gryga,

Details on the transaction:

Date of the transaction: 19.01.2017

Number of shares before trade: 0

Number of share acquired: 100

Number of shares after the trade: 100

Share price: NOK 35

Chairman of the Board John Afseth through his company Carpe

Diem Afseth AS,

Details on the transaction:

Date of the transaction: 19.01.2017

Number of shares before trade: 92 320

Number of share acquired: 7 680

Number of shares after the trade: 100 000

Share price: NOK 35

Board member Ingrid Teigland Akay through her company Hadean

Ventures AS,

Details on the transaction:

Date of the transaction: 19.01.2017

Number of shares before trade: 52 454

Number of share acquired: 6 000

Number of shares after the trade: 58 454

Share price: NOK 35

Board member Espen Tidemann Jørgensen through the company

Holta Life Sciences AS,

Details on the transaction:

Date of the transaction: 19.01.2017

Number of shares before trade: 1 928 496

Number of share acquired: 100 000

Number of shares after the trade: 2 028 496

Share price: NOK 35

Allocation of the new shares is conditional on the Private

Placement being completed. Completion of the Private

Placement is subject to, inter alia, approval of the

company's extraordinary general meeting in a meeting

expected to be held 30 January 2017.

This notification is given according to Merkur Market's

continuing obligations section 6.2.